Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database.

Date publication

décembre 2014

Journal

Current medical research and opinion

Auteurs

Membres identifiés du Cancéropôle Est :
Dr REILLY Patrick

Tous les auteurs :
Wendling D, Joshi A, Reilly P, Jalundhwala YJ, Mittal M, Bao Y

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/25252590

Résumé

To compare the risk of developing uveitis in patients initiating anti-tumor necrosis factor (anti-TNF) agents (adalimumab, etanercept, and infliximab) for ankylosing spondylitis (AS).

Mots clés

Adalimumab, Anti-Inflammatory Agents, therapeutic use, Antibodies, Monoclonal, therapeutic use, Antibodies, Monoclonal, Humanized, therapeutic use, Databases, Factual, Etanercept, Female, Humans, Immunoglobulin G, therapeutic use, Incidence, Infliximab, Male, Middle Aged, Receptors, Tumor Necrosis Factor, therapeutic use, Retrospective Studies, Risk, Spondylitis, Ankylosing, complications, United States, Uveitis, epidemiology, Young Adult

Référence

Curr Med Res Opin. 2014 Dec;30(12):2515-21